The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 349:505-506 July 31, 2003 Number 5
NextNext

Fibroblast Growth Factor 23 in Oncogenic Osteomalacia and X-Linked Hypophosphatemia

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Jonsson, K. B.
-PubMed Citation
To the Editor: Jonsson et al. (April 24 issue)1 report that fibroblast growth factor 23 (FGF-23) is markedly elevated in persons with oncogenic osteomalacia or X-linked hypophosphatemia. The authors do not discuss how an elevation in FGF-23 can lead to hypophosphatemia. Renal phosphate reabsorption is a major determinant of the plasma phosphate level and is largely regulated by the type 2 sodium-dependent phosphate cotransporter that is expressed in renal proximal epithelial cells. Yamashita et al.2 found that purified FGF-23 alone could not inhibit sodium-dependent phosphate uptake in a cultured renal proximal epithelial cell line (opossum kidney cells). Thus, FGF-23 might . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.